Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
18%(2 trials)

Phase Distribution

Ph phase_2
8
73%
Ph phase_1
3
27%

Phase Distribution

3

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
8(72.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

11 of 11 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(11)

Detailed Status

Completed11

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (27.3%)
Phase 28 (72.7%)

Trials by Status

completed11100%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_2

A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

NCT00910962
completedphase_2

Clinical Study to Test a New Drug to Treat Major Depression

NCT00976560
completedphase_2

A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00642148
completedphase_1

To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males

NCT00599612
completedphase_2

Study in Neuropathic Pain Patients With Peripheral Nerve Injury

NCT00969059
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT00910962Phase 2

A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

Completed
NCT00976560Phase 2

Clinical Study to Test a New Drug to Treat Major Depression

Completed
NCT00642148Phase 2

A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00599612Phase 1

To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males

Completed
NCT00969059Phase 2

Study in Neuropathic Pain Patients With Peripheral Nerve Injury

Completed
NCT00393146Phase 2

A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis

Completed
NCT00256919Phase 2

Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)

Completed
NCT00474864Phase 2

Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.

Completed
NCT00392587Phase 2

A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)

Completed
NCT00549653Phase 1

A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men

Completed
NCT00517543Phase 1

A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11